Synapse - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA) Meeting Abstract

Authors:	Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; Kelsen, D. P.; Ilson, D. H.; Aljallad, K.; Segal, M. F.; Millang, B. M.; Schultz, N.; Shah, P. M.; Solit, D. B.; Capanu, M.; Hechtman, J. F.
Abstract Title:	First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
Meeting Title:	2019 Gastrointestinal Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	37
Issue:	4 Suppl.
Meeting Dates:	2019 Jan 17-19
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2019-02-01
Language:	English
ACCESSION:	WOS:000489107600109
DOI:	10.1200/JCO.2019.37.4_suppl.62
PROVIDER:	wos
Notes:	Meeting Abstract: 62 -- Source: Wos